Alberta Research Council Incorporated

Glycomed, Inc.

H Rizk Hanna

Wasimul Haque

Richard H Smith

Andre P Venot

Mohammed A Kashem

Om P Srivastava

Pandurang V Nikrad

Robert M Ippolito

Cong Jiang

Ole Hindsgaul

Kevin R Holme

David R Bundle

Roman Szweda

Minghui Du

Geeta Srivastava

Frank W Barresi

Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a mammal.

Oligosaccharide glycosides having mammalian immunosuppresive and

Disclosed are methods for reducing the degree of antigen induced inflammation in a sensitized mammals. The disclosed methods employ oligosaccharide glycosides related to blood group determinants having a type I or type II core structure wherein the administration of such oligosaccharide glycosides is after initiation of the mammal's immune response but at or prior one-half the period of time required to effect maximal antigen-induced inflammation.

Time dependent administration of oligosaccharide glycosides related to

Disclosed are novel Lewis.sup.x and Lewis.sup.a analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.

Immunosuppressive and tolerogenic modified Lewis.sup.x compounds

Growing community of inventors

Edmonton, Canada

H Rizk Hanna